0.00Open0.25Pre Close0 Volume201 Open Interest2.50Strike Price0.00Turnover158.52%IV21.68%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.4413Delta0.5432Gamma11.30Leverage Ratio-0.0098Theta0.0003Rho4.99Eff Leverage0.0018Vega
MediciNova Stock Discussion
📊⚡️📊
MediciNova Inc - Patent Is Expected to Expire No Earlier Than May 26, 2042
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
MediciNova (NASDAQ: MNOV) announced it will receive monetary damages following the settlement of Sanofi-Novartis litigation. The company plans to use this non-dilutive fundingto support ongoing clinical development programs, particularly focusing on their late-stage pipeline targeting inflammatory, metabolic, and neurodegenerative diseases. The settlement validates MediciNova's in...
Medicinova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
No comment yet